| Optimal treatment with telaprevir for chronic HCV infection. | |
| | |
MedLine Citation:
|
PMID: 23286840 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Telaprevir is a recently approved direct-acting antiviral against hepatitis C virus (HCV) that works through inhibition of the NS3/4A serine protease inhibitor.Phase 2b and 3 studies have shown marked increase in sustained virological response rates in both treatment- naïve and treatment-experienced patients with HCV genotype 1 treated with a telaprevir-containing regimen compared with pegylated interferon (PEG-IFN) and ribavirin alone. The most commonly observed side effects of telaprevir therapy are anaemia to a greater degree than that observed with PEG-IFN/ribavirin alone; eczematous rash, which can be severe in a minority of patients; and anorectal discomfort. |
| | |
Authors:
|
Arun B Jesudian; Ira M Jacobson |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver international : official journal of the International Association for the Study of the Liver Volume: 33 Suppl 1 ISSN: 1478-3231 ISO Abbreviation: Liver Int. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-01-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160857 Medline TA: Liver Int Country: United States |
Other Details:
|
Languages: eng Pagination: 3-13 Citation Subset: IM |
Copyright Information:
|
Copyright © 2013 Elsevier Inc. |
Affiliation:
|
Division of Gastroenterology and Hepatology, Center for Study of Hepatitis C, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: In-Situ Crystallization Route to Nanorod-Aggregated Functional ZSM-5 Microspheres.
Next Document: Optimal treatment with boceprevir for chronic HCV infection.